NKTR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nektar Therapeutics (NKTR) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including favorable analyst upgrades, a promising drug pipeline, and robust market demand for its therapies. Despite recent financial challenges, the company's gross margin improvement and strong market sentiment make it a compelling long-term investment.
The technical indicators show a bullish trend. The MACD is positive and contracting, RSI is overbought at 91.349, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance levels (R1: 71.712, R2: 81.251), indicating strong upward momentum.
Analysts have significantly raised price targets and upgraded ratings, citing strong Phase 2b results for Rezpeg in atopic dermatitis and alopecia areata.
The atopic dermatitis market is projected to grow positively, with Nektar well-positioned to capitalize on demand.
Successful $460 million public offering reflects strong investor confidence.
Gross margin increased by 22.52% YoY, showcasing operational efficiency.
Hedge funds are selling, with a 1229.84% increase in selling activity last quarter.
Financial performance in 2025/Q3 was weak, with revenue dropping by 51.13% YoY and net income declining by 4.14% YoY.
RSI indicates overbought conditions, suggesting potential short-term volatility.
In Q3 2025, revenue dropped by 51.13% YoY to $11.79M, and net income fell by 4.14% YoY to -$35.52M. EPS declined by 29.70% YoY to -1.87. However, gross margin improved to 100%, up 22.52% YoY, indicating operational efficiency.
Analysts are highly bullish on NKTR. Multiple firms, including H.C. Wainwright, William Blair, and BTIG, have raised price targets and upgraded ratings, citing strong clinical trial results and the potential for Rezpeg to become a first-line treatment in atopic dermatitis. Price targets now range from $115 to $165, reflecting significant upside potential.
